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ACS acute coronary syndrome
Anti-Hsp-Ab antibodies against heat shock proteins
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Coronary heart disease (CHD) is the leading cause of morbidity and
mortality in the western world. Typical symptoms are chest pain and
dyspnoea on exertion and are the result of reduced blood flow to the
myocardium. The reduction in blood flow is in turn caused by
atherosclerotic plaques narrowing the coronary vascular lumen and thus
decreasing the nutritional blood flow. Sudden rupture or erosion of the
plaque leads to acute coronary syndrome (ACS), including unstable
angina, acute myocardial infarction and sudden cardiac death.
Atherosclerotic plaques prone to rupture are characterized by active
inflammation which is detected as increased numbers of activated
inflammatory cells (macrophages, T lymphocytes and mast cells) in the
lesions, and as elevated concentrations of inflammatory markers, such
as C reactive protein (CRP) and interleukine-6 (IL-6), in the circulation.
Serum iron and antibodies raised against heat shock proteins (Anti-Hsp-
Ab) are related to basic CHD pathophysiology and inflammation.
Aims of the study
The aim of the study was to investigate the role of inflammatory markers
in the classification and risk prediction of CHD. The first objective was to
study whether markers of activated inflammatory cells can be used in the
diagnostic classification and in the prediction of the clinical outcome in
ACS; the following markers were studied: monocyte chemoattractant
protein-1 (MCP-1) as a marker of monocytes/macrophages activation,
soluble interleukin-2 receptor (sILr-2) as a marker of T lymphocyte
activation and tryptase as a marker of mast cell activation. The second
objective was to study the role and interactions of CRP in ACS, and also
its role in primary prevention. The final aim was to assess the
association of the concentration of serum iron with the risk of CHD and
to find out whether Hsp-Ab may predict the risk of CHD.
Methods
Two different study populations were used for analyses. The first one
(ACS patients) included 183 patients, women and men aged between
40-80 years. Patients were recruited from three emergency hospitals in
Helsinki, Finland, between July 1998 and April 1999. The patients were
grouped into three categories according to the following clinical
courses: acute myocardial infarction with 59 patients, unstable angina
with 60 patients and acute angina with 64 patients. During the one-year
9follow-up 7 recurrent myocardial infarctions or unstable angina, 98
revascularisations and 11 cardiac deaths were recorded. MCP-1, sILr-2
and tryptase as well as systemic markers of the inflammatory
response, CRP and IL-6, were determined at hospital admission and
were studied in diagnostic classification and prediction of the recurrent
risk.
The second study population included dyslipidemic (non-high density
lipoprotein [HDL]-cholesterol > 5.2 mmol/l) men aged between 40 to 55
years who participated in the Helsinki Heart Study (HHS). HHS was a
double-blind, placebo-controlled primary prevention trial to test the
hypothesis that increasing HDL-cholesterol and simultaneously
decreasing LDL-cholesterol by study drug, gemfibrozil, will reduce the
incidence of CHD. Two-hundred forty-one subjects suffered either
myocardial infarction or coronary death, during the total 8.5-year study
and follow-up. These subjects were the cases for the present studies.
The controls were participants remaining free of coronary events,
matched for both drug treatment (gemfibrozil/placebo) and the
recruitment area.
Baseline levels of CRP, serum iron and Anti-Hsp-Ab, as well as pre-
event CRP levels were determined and used in the studies of
interactions and risk prediction.
Conclusions
There were no significant differences in blood concentrations of MCP-1,
sILr-2, and tryptase between the patient groups, and thus these markers
are not useful in the categorisation of patients with ACS. High
concentration (> median) of MCP-1 and sILr-2 were associated with
increased risk of recurrent coronary events during the one-year follow-
up.
In healthy, dyslipidemic, middle-aged men, those with high CRP
concentrations had a higher risk of myocardial infarction and coronary
death compared to those with lower CRP. If CRP levels were chronically
elevated, the associated risk was higher than when baseline or the pre-
event values were increased. The study on joint effects of CRP and
classical risk factors suggested that these factors were additive for
coronary risk.
In the unselected patient population which represents the everyday
clinical spectrum of ACS, CRP levels at hospital admission were not
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useful in the categorisation of patients into subtypes of ACS. CRP levels
were not associated with coronary events during the follow-up.
There was an association between low serum iron level and the risk of
myocardial infarction or coronary death. The effect of low iron is not
independent in the classical sense, and is related to the fact that chronic
infections and inflammation are accompanied by low serum iron levels.
There was a positive trend of increased myocardial infarction or coronary
death with increasing anti-heat shock protein60-antibody levels, but  the
effect was modest without simultaneous occurrence of classic risk
factors, such as hypertension and hypercholesterolemia.
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Introduction
Coronary heart disease (CHD) is the most common cause of morbidity
and mortality in the western world, despite prevention and treatments
for CHD, which have advanded to a great extent (Fuster 1999). The
disease affects apparently healthy men and women as well as those
with a previous diagnosis of CHD. In both cases, the present screening
methods are insufficient for the reliable prediction of coronary events.
Consequently, new, more accurate methods are needed.
Coronary atherosclerosis is the cause of CHD (Davies et al. 1985,
Fuster et al. 1992). Typical symptoms are chest pain and dyspnoea on
exertion and are the result of reduced blood flow to myocardium. The
reduction in blood flow is, in turn, caused by atherosclerotic plaques
narrowing the coronary vascular lumen and thus decreasing the
nutritional blood flow. In the event of sudden rupture or erosion of the
plaque, a thrombogenic mass bulges into the arterial lumen, activates
thrombocytes and the coagulation system. The result of this cascade of
events is an occlusive thrombus which immediately reduces or
discontinues the blood flow to the myocardium and leads to ACS
including unstable angina, acute myocardial infarction or sudden
cardiac death (Davies et al. 1985, Fuster et al. 1992, Falk et al. 1995).
Plaque rupture is the main cause of fatal acute myocardial infarction
and / or sudden cardiac death.
Atherosclerotic plaques which are vulnerable to rupture are
characterised by active inflammation and certain morphological and
functional features (Naghavi et al. 2003). Active inflammation is
detected as increased numbers of inflammatory cells in atherosclerotic
lesions (Jonasson et al. 1986, Van der Wal et al. 1994) and as elevated
concentrations of inflammatory markers in the circulation
(Liuzzo et al. 1994, Haverkate et al. 1997). Major inflammatory cells,
macrophages, T lymphocytes and mast cells, produce and secrete
inflammatory markers detectable in the circulation. Inflammatory
markers are important mediators in the diversified and multi-step
cascade of atherosclerosis which ultimately leads to the rupture of the
atherosclerotic plaque. The following markers were studied: monocyte
chemoattractant protein-1 (MCP-1) as a marker of
monocytes/macrophages activation, soluble interleukin-2 receptor
12
(sILr-2) as a marker of T lymphocyte activation and tryptase as a
marker of mast cell activation.
CRP is an acute phase protein which increases in various inflammatory
and infective states. Recent data suggest that inflammation is deeply
involved in the pathogenesis of atherothrombosis (Ross 1999).
Elevated CRP levels predict future cardiovascular events both in
apparently healthy population and in those with CHD (Liuzzo et al.
1994, Haverkate et al. 1997, Danesh et al. 2000). Increased CRP
concentrations may indicate widespread inflammation and instability of
atherosclerotic plaques in coronary arteries (Lombardo et al. 2004).
CRP was studied as a general inflammatory marker in the prediction
and categorization of CHD.
It has been suggested that iron plays a role in oxidative damage of
lipoproteins and thus in the pathophysiology of atherosclerosis.
However, the epidemiological association between iron status and
CHD has remained controversial (Danesh et al. 1999). Inflammation
and infection may influence iron metabolism resulting in low serum iron
levels. The association between serum iron and risk of CHD was
studied.
Nucleated cells express heat shock proteins (Hsp), in response to
environmental stress. Increased expression of Hsp has been detected
in the cells of atherosclerotic lesions (Kleindienst et al 1993, Xu et al
1993) and elevated antibodies against heat shock proteins (Anti-Hsp-
Ab) levels have been shown to be associated with human
atherosclerosis (Hoppichler et al. 1996, Birnie et al. 1998). The
association between Anti-Hsp-Ab and coronary risk was studied.
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Review of literature
Coronary atherosclerosis
Atherosclerotic lesions develop in medium-sized and large arteries and
may cause circulation disturbancies in the heart, brain and extremities.
The earliest sign of atherosclerosis in the arterial intima is a collection
of lipid-laden foam cells (Stary et al 1994). These cells are monocyte-
derived macrophages which have ingested oxidized LDL via their
scavenger receptors, probably to protect tissues against toxic effects of
oxidized LDL. These macrophages are subsequently transformed to
lipid-laden foam cells (Stary et al. 1994). These early lesions, fatty
streaks, can already be found during childhood (Pesonen et al 1975).
Indeed, in healthy Finnish children who died violently, intimal
thickenings of the coronary arteries were found in 53% of 75 cases,
even in children under 5 years (Hirvonen et al 1985).
During the following decades early lesions advance, and accumulation
of lipids, fibrous tissue and inflammatory cells, growth of smooth
muscle cells and endothelial dysfunction characterize coronary
atherosclerosis (Stary et al 1994, Stary 1995, Ross 1999). Irregular
thickenings of the arterial intima restrict the lumen of coronary artery
and reduce the nourishing blood flow to the myocardium. A fibrous cap
covers the plaque and separates it from the vascular lumen. This cap
varies in thickness and content of collagen, smooth muscle cells and
inflammatory cells (Hansson et al 1988, Stary et al 1994, Ross 1999).
An atherosclerotic plaque, which is prone to rupture is characterized by
a large, lipid-rich atheromatous core and a thin fibrous cap, in which
both collagen content and smooth muscle cell density are reduced.
Moreover, the amount of inflammatory cells in the plaque is increased
(Van der Wal et al 1994, Falk et al 1995). In the event of erosion or
rupture of atherosclerotic plaque, exposure of its thrombogenic content
into the lumen of the coronary artery activates thrombocytes and the
coagulation system. Activated thrombocytes aggregate at the site of
rupture and together with the activated coagulation system, form a
thrombus, which may partially or even totally occlude the lumen of the
coronary artery (Falk et al 1995, Schroeder et al 1995). With
decreasing or complete cessation of blood flow, the myocardium
becomes ischaemic. As a consequence, the clinical setting for ACS,
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namely unstable angina, acute myocardial infarction or sudden cardiac
death, develops.
The relation between elevated serum cholesterol and atherosclerosis
was first published in the 1930s by Müller and Thannhauser. Since
then the causal role of elevated serum cholesterol in the pathogenesis
of atherosclerosis has been well documented (Kannel et al 1971,
Neaton et al 1992, Pekkanen et al 1992). Further studies have shown
that the principal causal component in the development of
atherosclerosis is LDL cholesterol, whereas HDL seems to exert a
protective effect (Castelli et al 1992). Smoking, hypertension, diabetes,
obesity, physical inactivity and genetic inheritance are important risk
factors in the progression of primary atherosclerosis
Atherosclerosis and inflammation
In the 1850s Rudolf Virschow, the founder of cellular pathology,
suggested that a low grade injury to the arterial wall resulted in a type
of inflammatory reaction. In the end of 19th century, atherosclerosis was
considered to be an aging process of arteries. Sir William Osler stated
that “longevity is a vascular question, a man is as old as his arteries “,
in his “Principle and Practice of Medicine”. He was the first to suggest
that infection may be involved in the pathogenesis of the
atherosclerosis. The response-to injury hypothesis of atherosclerosis
was presented in 1973 to explain the fibroproliferative response to the
accumulation of lipids in the arterial vessel wall. New knowledge of
cellular and molecular biology of the arterial wall was incorporated into
the theory (Ross et al 1973, Ross 1986). More recently, the
inflammation hypothesis has been supported by an enormous amount
of published data, and presents a modern view of the pathophysiology
of atherosclerosis (Ross 1999).
In human atherosclerotic lesions, about 80 % of inflammatory cells are
macrophages, 10-20 % T lymphocytes and only a small percentage are
mast cells (Moreno et al 1994, Kaartinen et al 1994), Figure 1. These
inflammatory cells are found in the fibrous cap, especially in the
shoulder region of the atherosclerotic lesion, and in the intima. A
variety of antigens, adhesion molecules and receptors are detected on
the surfaces of activated inflammatory cells (Jonasson et al 1986,
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Hansson et al 1988, Hansson et al 1989, Van der Wal et al 1994,
Moreno et al 1994). Activated inflammatory cell ssynthesize cytokines
and adjacent cells are stimulated by these molecules (Mazzone et al
1993).
Figure 1. Schematic view of possible associations of inflammatory markers related to
the present study, in the pathogenesis of atherosclerosis:
A. Modified LDL induces expression of adhesion molecules in endothelial cells
B. Activated macrophages and foam cells produce several chemokines
(including IL-6, MCP-1), growth factors and enzymes (proforms of matrix-
metalloproteinases)
C. T lymphocytes produce chemokines (including interferon-gamma, IL-2) and
activate macrophages to express proforms of matrix-metalloproteinases
D. Mast cells  releases enzymes (including tryptase, chymase) which activate
matrix-metalloproteinases
MCP-1 induces migration of monocytes into intima where they differentiate into
macrophages. Cytokines have several inflammatory actions, including
inflammatory cell recruitment and enhancement of production of other cytokines.
The mast cell proteases and matrix-metalloproteinases degrade subendothelial
tissue and may thus predispose to endothelial erosion or rupture of the
atherosclerotic plaque.
In plaques with erosion or rupture, the numbers of inflammatory cells in
tissue samples are greater compared with non-ruptured plaques
(Arbustini et al 1995). Accordingly, macrophage-rich areas are more
frequently found in plaque tissue samples in patients with unstable
angina than in plaque tissue samples from patients with stable angina
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(Moreno et al 1994). Plaques in patients with unstable angina have an
increasing prevalence of inflammatory cells and higher cellularity within
plaques compared with plaques in patients with stable angina. This
finding confirms the correlation between histological structure of
coronary lesion and the clinical presentation (Depre et al 1997).
Activated mast cell, co-localized with other inflammatory cells are found
in plaques at all developmental stages of atherosclerosis and in
increasing numbers with the progression of atherosclerotic lesions
(Kaartinen et al 1994).  Indeed, atherosclerotic lesions, obtained from
patients with unstable angina and acute myocardial infarction, have
higher numbers of mast cells compared to lesions obtained from
patients with stable angina (Kaartinen et al 1994, Kovanen et al 1995,
Kaartinen et al 1996, Kaartinen et al 1998).
Interleukine-6 (IL-6) is a pro-inflammatory cytokine and a mediator of
production of several acute phase proteins, such as C-reactive protein
(CRP), a systemic marker of inflammation. Increased levels of IL-6 and
CRP predict increased risk of CHD in apparently healthy, asymptomatic
women and men (Kuller et al 1996, Ridker et al 1997, Ridker et al
1998, Koenig et al 1999, Danesh et al 2000, Ridker et al 2000). In
patients with stable or unstable angina, elevated CRP concentrations
indicate an increased risk of cardiovascular events, such as cardiac
death, myocardial infarction, and the need for coronary
revascularization (Liuzzo et al 1994, Haverkate et al 1997).
Inflammation plays a role in all stages of atherosclerosis (Ross 1999).
Active inflammation, as seen by increased numbers of inflammatory
cells in atherosclerotic plaques and increased levels of systemic
inflammatory markers in the circulation, are associated with increased
cardiovascular events both in apparently healthy subjects and in those
with CHD.
It has been claimed that other inflammatory diseases, such as psoriasis
and rheumatoid arthritis, increases the incidence of CHD mortality
(McDonald et al 1978, Myllykangas-Luosujarvi et al 1995).
Inflammation and endothelial dysfunction, related to rheumatoid
arthritis, might be important CHD risk factors in these patients
(Hurlimann et al 2004). In the future it will be apparent, if new effective
anti-inflammatory treatments strategies for rheumatoid ahrtritis, which
also improve endothelial function and reduce inflammation, may reduce
CHD events.
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Inflammatory markers
General markers of inflammation
Erythrocyte sedimentation rate, white blood cell count, fibrinogen, and
C-reactive protein (CRP), are all regarded as general markers of
inflammation. The concentrations of inflammatory markers indicate the
severity of inflammation and have been associated with CHD risk.
One such indicator, erythrocyte sedimentation rate is indicative of
plasma acute phase protein concentration, mainly that of fibrinogen. It
also indicates red cell aggregation and blood viscosity. It is elevated in
acute and chronic diseases with inflammation and tissue necrosis. In
the meta-analysis of four population-based, prospective studies, an
increased incidence of CHD was detected in those individuals with a
mean erythrocyte sedimentation rate of 15 mm/h giving a risk ratio of
1.33, over those with a mean erythrocyte sedimentation rate of 5 mm/h
(Danesh et al 2000).
Recently, two large population-based cohort studies with apparently
healthy women and men in Scandinavia demonstrated a similar result.
Moreover, erythrocyte sedimentation rate emerged as a strong
predictor of CHD mortality after 17-23 years after the blood test was
performed (Erikssen et al 2000, Andresdottir et al 2003). Elevated
erythrocyte sedimentation rate values indicated a raised cardiovascular
risk, even after adjustments for age and coronary risk factors. However,
none of these studies made adjustments between erythrocyte
sedimentation rate and serum fibrinogen, which is an acute phase
protein that plays a dominant role in the falling rate of erythrocytes
through plasma.
Fibrinogen is the main coagulation protein in the plasma and an
important determinant of blood viscosity. It is also an acute phase
protein, produced in the liver, and it is increased by acute and chronic
infectious and inflammatory causes. In addition, smoking increases,
whereas its cessation decreases fibrinogen levels (Folsom 1995). A
meta-analysis of 18 prospective studies, with a mean age at base-line
of 56 years and with mean follow-up time of 8 years, releaved a
combined risk for CHD of 1.8 (95% CI 1.6-2.0), when those individuals
in the highest fibrinogen tertile were compared to those in the lowest
tertile (mean fibrinogen levels 0.35 vs. 0.25 g/dl). Most of the studies
had made adjustments for age, sex and smoking. This analysis
involved a total of 4018 cases with CHD (Danesh et al 1998).
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The association between white blood cell count and CHD is based on
several reports. In a combined study comprising 7 prospective trials, in
which 5336 CHD cases were analysed, a comparison of the top third of
single baseline white blood cell count measurements gave a combined
risk ratio for CHD of 1.5 (95%CI 1.4-1.6) (Danesh et al 1998). The risk
ratio was calculated after adjustments for age, sex, smoking and
standard vascular risk factors. Furthermore, the estimated white blood
cell count counts for the top and bottom thirds were 8.4 and 5.6x109/l.
A similar result was reported for 8914 adults aged between 30 to 75
years over a 17-year follow-up in the NHANES II Mortality trial(Brown
et al 2001). Subjects with a white blood cell count count > 7.6 were at
increased risk of death from CHD, (relative risk = 1.4; 95% CI 1.1-1.8)
compared to those with white blood cell count count < 6.1 (Brown et al
2001). Elevated white blood cell count count at hospital admission
appears to predict the risk of increased CHD mortality in patients with
acute myocardial infarction (Furman et al 2004). An increased white
blood cell count prior to percutaneous coronary intervention was
reported to predict an increased risk of mortality (Gurm et al 2003).
C-reactive protein (CRP)
CRP is an acute phase protein, which is produced as a response to
infection, inflammation and tissue necrosis. In the mid 1990s,
immunoassays with greater sensitivity revealed that, CRP values less
than 10 mg/l, which were previously considered normal in everyday
clinical practice, are associated with disease activity.
The automated nephelometric and turbidimetric immunoassays
developed in the 1970s and the homogeneous enzyme and
fluorescence polarization methods developed in the 1980s had limited
sensitivity in the lower range of CRP concentrations. Thus, CRP values
less than 10 mg/l, remained undetected until new, more sensitive
immunoassays became available.
CRP has a long half-life, 19 hours. In addition, it has no diurnal or
seasonal variation nor does it have any correlation with nutritional
status, or sex in healthy populations (Vigushin et al 1993, Meier-Ewert
et al 2001). Plasma concentrations of CRP are determined by its
production rates (Meier-Ewert et al 2001). Thus, a single, non-fasting
determination of CRP reflects the presence or absence of ongoing
pathological processes stimulating CRP synthesis.
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Activated inflammatory cells produce cytokines, of which IL-6 and to a
lesser extend IL-1 are major determinants for the production of CRP
and other acute phase proteins in the liver (Gauldie et al 1992, Le et al
1989)
After stimulation of the hepatocytes by cytokines, levels of CRP in the
blood start to increase within 6 hours. These concentrations can
increase up to 1000-fold or even more (Vigushin et al 1993).
Smoking and obesity are positively correlated with CRP levels,
whereas weight loss and cessation of smoking decrease CRP values
(Danesh et al 1999, Yudkin et al 1999, Rohde et al 1999). Adipose
tissue is an important site for the production of IL-6, a major up-
regulator of CRP gene expression in the liver. As much as 30 % of
circulating IL-6 originates from adipose tissue, and this may be one
explanation for elevated CRP levels in obese persons (Yudkin et al
1999).
Frequent physical activity is associated with decreased CRP levels.
This may indicate lower systemic inflammation in those engaged in
physical activity compared with those not engaged in any physical
activity (Ford et al 2002).
The median CRP values in the general population (5748 adults from
two study cohorts) with ages between 25-74 years rose with age
(Hutchison et al 2000). For example, mean CRP concentration
approximately doubled with age, from 1.13 mg/l among those men
aged between 35-44 years to 1.93 mg/l among those men aged 65-74
years (Hutchison et al 2000). The corresponding CRP values in women
were 1.08 mg/l and 2.22 mg/l.
Indeed, elevated CRP concentrations are associated with the
development of symptomatic peripheral arterial disease (Ridker et al
1998), Alzheimer’s disease (McGeer et al 2000), age-related macular
degeneration (Seddon et al 2004), colorectal cancer (Erlinger et al
2004) and the deterioration of renal function in transplant recipients
(Teppo et al 2003). Elevated CRP is also an independent predictor of
pre-eclampsia in lean women (Qiu et al 2004).
Significant positive associations (p <0.05) between CRP levels and
age, systolic and diastolic blood pressure, total cholesterol,
triglycerides, lipoprotein(a), apolipoprotein B, and fibrinogen were
reported in a cross-sectional survey of 1,172 apparently healthy men. A
significant inverse association (p value < 0.02) was also observed for
HDL-cholesterol (Rohde et al 1999).
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Even CRP levels in the high sensitivity range (<10mg/l) were
associated with future cardiovascular events in apparently healthy,
asymptomatic women (Ridker et al. 1998, Ridker et al. 2000, Ridker et
al. 2002), men (Kuller et al. 1996, Ridker et al. 1997, Koenig et al.
1999, Danesh et al. 2000), and in the elderly (Tracy et al. 1997).
Elevated CRP levels had a stronger association with cardiovascular
risk than LDL- cholesterol in the follow-up study of 27939 apparently
healthy American women. Moreover, this association was independent
of age, smoking, cholesterol, diabetes and hypertension (Ridker et al.
2002). In a meta-analysis of 14 prospective, population-based studies,
based on 1953 cases of CHD, a combined risk factor of 1.9 (95% CI
1.5-2.3) for CHD in subjects in the highest tertile (>2.4 mg/l) compared
to those in the lowest tertile of CRP concentrations (< 0.9 mg/l) was
reported . These calculations were made after adjustmenting for age,
smoking and some standard vascular risk factors (Danesh 2000).
Recently, the American Heart Association gave a statement of risk
category for cardiovascular disease based on the available evidence;
CRP > 3.0 mg/l high, 1.0-3.0 mg/l moderate and < 1.0 mg/l low risk
(Pearson et al. 2003). However, an updated meta-analysis which
added another 5115 cases of CHD from another 12 studies, indicated a
lower odds ratio for CHD risk, 1.49 (95 % CI 1.37 to 1.62), in subjects
with baseline CRP concentrations in the top third compared to those in
the bottom third of the distribution (Danesh 2004). Moreover, CRP
concentration had only a marginal predictive value when compared to
classical risk factors, including cholesterol concentration and smoking.
The authors suggested that recent recommendations regarding the use
of determinations of C-reactive protein in the prediction of CHD may
need to be re-evaluated (Danesh 2004).
In two studies, CRP concentrations were positively associated with the
degree of CHD as detected by angiography, i.e. the number of
stenosed coronary arteries and even with more extended
atherosclerotic disease in peripheral arteries determined as by ultra
sonography (Heinrich et al. 1995, Tataru et al. 2000). On the other
hand, CRP levels had a poor correlation with the results of tests
measuring coronary calcification, as measured by electron beam
computerized tomography in asymptomatic postmenopausal women
(Redberg et al. 2000). A weak or nonexistent association has been
reported between CRP concentration and intima-media thickness, an
indicator of subclinical atherosclerosis, as assessed by B-mode
ultrasound (Folsom et al. 2001, Wang et al. 2002).
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Among 2121 patients with angina (1030 unstable, 743 stable, 348
atypical angina), there was about a two-fold increase in the risk of
myocardial infarction and sudden cardiac death for CRP concentrations
in the fifth quintile (> 3.6 mg/L), compared with CRP values in the other
four quintiles during two years of follow-up (Haverkate et al. 1997).
Several studies have demonstrated, that elevated CRP levels indicate
an increased risk of cardiovascular events (cardiac death, myocardial
infarction, and the need for coronary revascularization) in patients with
unstable angina (Liuzzo et al. 1994, Haverkate et al. 1997, Toss et al.
1997, Morrow et al. 1998).
High peak CRP value in the first days after an acute myocardial
infarction predicted heart failure during the hospital stay and cardiac
mortality during the first 6 months (Pietila et al. 1996).
In multiple prospective and cross-sectional studies a positive
association between elevayed CRP levels and cardiovascular morbidity
and mortality has been demonstrated. It has been proposed that CRP
reflects the overall inflammatory burden of atherosclerotic disease and
indicates widespread inflammation and multiple complex
atherosclerotic plaques in coronary and carotid arteries (Lombardo et
al. 2004). However, there are data suggesting a possible direct role of
CRP in the pathogenesis of atherosclerosis. For example, it has been
suggested that CRP mediates complement activation in early
atherosclerotic lesions and activates the classical complement pathway
(Volanakis et al. 1982, Torzewski et al. 1998). Moreover, CRP has also
been reported to stimulate tissue factor production by human peripheral
blood monocytes in vitro and could in that way have a procoagulant
effect (Cermak et al. 1993). It has also been reported that CRP recruits
monocytes by receptor-mediated chemotaxis into the arterial wall
(Torzewski et al. 2000) and it has been founded co-localised with foam
cells in atherosclerotic lesions (Torzewski et al. 1998). Nevertheless,
the pathobiological significance of these findings in the progression of
atherosclerosis remains unclear.
In the clinical setting, the role of CRP in cardiovascular risk estimation
is still ambiguous and needs to be further defined. However, its use in
the primary and secondary prevention for CHD has been suggested to
be useful (Smith et al. Circulation 2004).
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Cytokines, specific markers involved in inflammation
Cytokines are proteins that affect the behavior of other cells. Nearly all
nucleated cells are capable of synthesizing these proteins and, in turn,
responding to them. Most cytokine genes are expressed only when
cells are stimulated by noxious events, including infection,
inflammation, heat shock, hyperosmolarity and ultraviolet light.
Cytokines are multipotent mediators of inflammation and immunity with
generalized action in host defence and pathology. Cytokines include
interferons, interleukins, tumor necrosis factors and growth factors.
Chemokines are a subset of cytokines that cause the migration of
leukocytes along the chemokine gradient. More than 50 human
chemokines and 18 chemokine receptors have been discovered so far
(Szekanecz 2000).
There are two types of T cells, characterized by surface glycoprotein
antigen; helper T cells that carry CD4 and cytotoxic T lymphocytes that
carry the CD8 marker. Helper T cells can be divided into TH1 and TH2
cells according to the cytokines they release on antigen contact
(Winchester R 2000). Both cell subgroups secrete several cytokines
which tend to sustain their own development and antagonize cytokines
produced by TH1/ TH2 cell group (Winchester 2000). In general, TH1
favours the promotion of cellular immunity, whereas TH2 favours the
promotion of humoral immunity. TH1-derived cytokines are pro-
inflammatory leading to macrophage activation and are found to
associate with the acceleration of experimental atherosclerosis
(Whitman et al. 2000). TH2-derived cytokines tend to limit the cytotoxic
potential of macrophages and to reduce pro-inflammatory mediators
(Winchester 2000). The predominance of TH1 lymphocytic
subpopulation as well as the expression of TH1 response-promoting
cytokines, especially IFN- ? and IL-2 has been demonstrated in
atherosclerotic lesions (Frostegard et al. 1999).
Macrophages are highly active cells and they are very important in
converting immune responses into inflammatory reactions. Activated
macrophages produce cytokines, including interleukin-1 and tumour
necrosis factor. In addition they synthetize various enzymes ( including
proteases, elastase, collagenase, plasminogen activator, and
procoagulants) that are important in inflammatory processes. CD4 T
lymphocytes recognize foreign antigens and defend the host by
reacting against them with mechanisms of cellular and humoral
immunity. After antigen recognition T lymphocytes become activated,
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they proliferate, expand clonally, and migrate to tissues where
recognized antigens are present. The adhesion cascade with
chemokines, specific adhesion molecules and integrins help T cells to
find their way from the blood stream to the site of inflammation or
infection.
Interleukine-2 (IL-2)
TH1 cells produce interleukine-2 (IL-2) which induces further T-cell
growth and co-stimulates B-cell growth and differentiation. IL-2
mediates its action on target cells by binding to their surface
receptors. IL-2 receptors (IL-2r) are expressed within 24 hours after
T-cell stimulation and disappear within a few days, whereas the
soluble IL-2 receptors (sIL-2r) remain in the plasma much longer
(Liuzzo et al. 1999, Liuzzo et al. 2000).
Activated T-cells are present early in atherosclerotic lesions.
(Jonasson et al. 1986, Hansson et al. 1989) The mechanism
involved in T-lymphocyte activation has not been clearly defined,
but the role of specific antigens such as oxidized LDL, heat-shock
proteins, bacterial and viral proteins has been suggested (Stemme
et al. 1995).
In patients with unstable angina an increase in circulating activated
T-lymphocytes has been reported (Neri Serneri et al. 1997, Caligiuri
et al. 1998). Furthermore, increased levels of CD4+ T lymphocytes
in patients with unstable angina have also been found. These T
cells produce extensively IFN- ?, a pro-inflammatory cytokine that
mediates macrophage activation, enhances inflammatory cell
recruitment and chemokine production, including IL-2 and IL-4
(Liuzzo et al. 1999). Moreover, a subset of activated T lymphocytes,
CD4+CD28null T cells have been demonstrated in the peripheral
blood of patients with stable and unstable angina, but the median
frequency of T lymphocytes is 10-fold in patients with unstable
angina. Furthermore, in patients with unstable angina, CD4+CD28null
T cells have been demonstrated both in peripheral blood and in
culprit coronary plaques, but interestingly not in non-culprit plaques.
In different patients these CD4+CD28null T cells show clonality,
shared receptor sequences, in their antigen receptors suggesting a
chronic stimulation by a common antigen (Liuzzo et al. 2000).
Patients with a high percentage of activated T lymphocytes in
peripheral blood tend to have higher sIL-2r concentration compared
with patients with a lower percentage of activated T lymphocytes
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(Caligiuri et al. 1998). The highest sIL-2r levels are reported 7-15
days after the last episode of angina in patients whose clinical
condition is stabilizing (Neri Serneri et al. 1997, Caligiuri et al.
1998).
Interleukine-6 (IL-6)
IL-6 is a cytokine that exerts multiple activities on different types of
cells. IL-6 has pro-inflammatory properties, including induction of
both B-cell and monocyte differentiation and activation of T
lymphocytes (Le et al. 1989). IL-6 is the main stimulator of the
production of the most acute-phase proteins and is the main
determinant for the production of CRP in the liver. After hepatocytes
have been stimulated by IL-6, serum concentrations of C-reactive
protein, amyloid A, fibrinogen, and ferritin increase and serum
concentrations of transferrin and albumin decrease (Le et al. 1989,
Gauldie et al. 1992). IL-6 and to a lesser extend IL-1 are major
determinants for the production of CRP in the liver (Le et al. 1989,
Gauldie et al. 1992).
IL-6 can be produced by various cell types including
monocytes/macrophages, T lymphocytes, smooth muscle cells and
endothelial cells (Kishikawa et al. 1993). Other cytokines, such as
tumor necrosis factor alfa, and interleukin-1 enhance the production of
IL-6 (Le et al. 1989). Interestingly, tumor necrosis factor alfa,
interleukin-1 and interleukin-2 receptors are found in early stage
atherosclerotic lesions, in the grossly normal aortic wall, where IL-6 is
not present. However, IL-6 is present in more advanced atherosclerotic
lesions in the aortic wall and in the shoulder regions of atherosclerotic
plaques, co-localized with tumor necrosis factor alfa and interleukin-1
(Kishikawa et al. 1993). Besides its secretion by inflammatory cells in
atherosclerotic lesions, IL-6 is produced by adipose tissue. Obesity and
insulin resistance are associated with increased concentrations of IL-6
and CRP (Yudkin et al. 1999). Many noxious stimuli, such as viruses
and bacterial endotoxins can induce expression of IL-6 (Le et al. 1989).
Data from prospective population-based studies including apparently
healthy persons suggested that elevated levels of IL-6 predict the risk
of myocardial infarction and death, but not angina (Ridker et al. 2000,
Luc et al. 2003). The risk of myocardial infarction increased 38% with
each quartile increment of baseline IL-6 level (Ridker et al. 2000).
Although CRP was positively correlated with IL-6, a significant
association remained between IL-6 level and the risk of myocardial
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infarction after adjustment with CRP (Ridker et al. 2000, Luc et al.
2003). Patients with stable angina had higher IL-6 concentration than
healthy controls, and patients with unstable angina had higher IL-6
concentration than patients with stable angina (Biasucci et al. 1996,
Ikonomidis et al. 1999). Patients with unstable angina and with
complicated in-hospital course (urgent need for revascularisation), had
higher IL-6 concentration both on hospital admission and during the 48
hours follow-up compared with those patients with unstable angina and
without cardiovascular events during their hospital stay (Biasucci et al.
1996 Biasucci et al. 1999). It was noteworthy, that markers for
myocardial damage were negative in both patient groups. In two
studies there was no correlation between levels of IL-6 and creatinine
kinase in patients with myocardial infarction (Sturk et al. 1992, Miyao et
al. 1993). There was no correlation between IL-6 and CRP at hospital
admission, but peak levels of IL-6 and CRP correlated significantly
(Sturk et al. 1992, Miyao et al. 1993).
Interleukin-6 levels correlate positively with CRP levels in several
studies (Sturk et al. 1992, Miyao et al. 1993, Biasucci et al. 1996,
Ikonomidis et al. 1999, Ridker et al. 2000). However, in another study
such positive association has not been noted (Luc et al. 2003). This
discrepancy between studies may be related to different timing of blood
tests and to the fact that there is a different time course and
disappearance (half-life) between the peak levels of IL-6 and CRP. IL-6
has a much shorter half-life (4 hours) compared to the half-life of CRP
(19 hours).
IL-6 is a powerful cytokine and mediator of production of many acute
phase proteins. Elevated concentration of IL-6 appears to be
associated with increased cardiovascular events in apparently healthy
subjects and in patients with unstable angina (Biasucci et al. 1996
Biasucci et al. 1999, Ikodomikis 1999). It has been hypothesized that
elevated IL-6 reflects the extent of chronic inflammation in
atherosclerotic plaques, and might indicate increased plaque instability.
(Biasucci et al. 1996, Biasucci et al. 1999, Ridker et al. 2000, Luc et al.
2003). Moreover, in the older population, the association between IL-6
and mortality is not limited to cardiovascular causes only, but even to
causes unrelated to cardiovascular mortality (Volpato et al. 2001).
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Monocyte chemoattractant protein-1 (MCP-1)
Monocyte chemoattractant protein-1 (MCP-1) is a key chemokine in the
recruitment and activation of monocytes and other inflammatory cells to
the sites of inflammation. Increased expression of MCP-1 has been
detected in the cells of atheromatous plaques (Terkeltaub et al. 1998).
The effects of MCP-1 are mainly mediated by receptors (CCR-2) on the
target cell surfaces (Mukaida 1998).
MCP-1 is the main chemokine, which regulates migration and
infiltration of monocytes-macrophages and T lymphocytes from the
circulation into the arterial wall, a key feature in atherosclerosis (Nelken
et al. 1991). Interestingly, MCP-1 induces its own production in
monocytes and thus further enhances the focal accumulation of
monocytes (Vestergaard 1997).
Experimentally it has been demonstrated that MCP-1 induces pro-
inflammatory cytokines (IL-6) in human arterial smooth muscle cells,
matrix metalloproteinases in human fibroblasts, and adhesion
molecules in human monocytes (Terkeltaub et al. 1998, Egashira
2003). It has been suggested that all these MCP-1 related events
accelerate atherosclerotic progression in the vessel wall.
MCP-1 expression is related to the amount of the macrophage
infiltration and even to the extent of atherosclerosis. Accordingly,
increased expression of MCP-1 has been found in macrophage-rich
areas of atherosclerotic lesions, but in contrast MCP-1 is not present in
normal artery walls (Nelken et al. 1991, Ylä-Herttuala et al. 1991).
After vascular injury, caused by balloon injury or stenting, inflammatory
and proliferative cells are shown to express MCP-1 (Hokimoto et al.
2002). Intimal hyperplasia and accelerated atheroma formation after
vascular injury are decreased when MCP activity is inhibited
experimentally by gene or drug therapy (Hokimoto et al. 2002, Usui et
al. 2002). Experimental inhibition of MCP-1 activity attenuates both the
formation and progression of primary atherosclerotic lesions (Ni et al.
2001, Inoue et al. 2002).
Elevated levels of MCP-1 are positively associated with hypertension
(Parissis et al. 2000), with hypercholesterolemia (Garlichs et al. 2001)
and with older age (Inadera et al. 1999), i.e. risk factors for
cardiovascular diseases.
Increased levels of MCP-1 have been found in patients with unstable
angina and elevated concentrations of MCP-1 are associated with
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increased risk of myocardial infarction and death (Aukrust et al. 2001,
Hojo et al. 2002, deLemos et al. 2003). Patients with acute myocardial
infarction have higher MCP-1 concentrations compared with patients
with stable angina (Matsumori et al. 1997).
After PCI or stenting of coronary artery lesions, increased production of
MCP-1 appears to predict a higher risk of restenosis (Cipollone et al.
2001).
These findings might indicate that MCP-1 expression is not only related
to progression and instability of atheromatous plaque, but also to the
formation of restenotic lesions.
Tryptase
Tryptase is a serine protease produced by mast cells. Mast cells are
found in the dermis, throughout the lungs and in the mucosal and
submucosal layers of the bowel, i.e. on body surfaces where they can
act as a first-line defence cells against foreign antigens (Schwartz
1987). In the tissues, mast cells are usually located around small blood
vessels, notable venules. Indeed, mast cells typically reside
subendotelially. On the other hand, a small proportion of mast cells can
be found in large and midsize arteries, where they also typically locate
subendothelially either in the intima layer or around the vasa vasorum
in the adventitia (Kovanen et al. 2000).
All human mast cells contain tryptase, histamine and a varying
percentages of them also contain chymase, another serine protease
(Irani et al. 1986). Two types of tryptase are expressed by mast cells,
?- and ?-tryptase. The ?-type is quantitatively the predominant type in
normal subjects and it has been suggested that it is released
constitutively from mast cells in an inactive form (Schwartz et al. 1995).
The ?-type is stored in mast cell granules and released in the active
form during degranulation (Schwartz et al. 1989).
The classical type of mast cell stimulation occurs in allergic reactions,
especially in anaphylaxis, and is IgE-mediated. In anaphylactic
reactions, activated mast cells release tryptase in large quantities and
increased serum levels of the tryptase enzyme protein are measurable
30-60 minutes after the onset of symptoms (Schwartz et al. 1989). The
in-vivo half-life of tryptase protein is approximately 2 hours.
Consequently, serum tryptase levels usually return to the normal range
within 12-14 hours after relief of the allergic symptoms (Schwartz et al.
1989).
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Mast cells need to be activated before being able to degranulate and
secrete tryptase into their micro-enviroment. Besides the classic IgE-
mediated route, another pathway for stimulation is suggested. Other
immunologically activated cells, such as macrophages and T
lymphocytes, have been shown to release mast-cell stimulating factors
(Sedgwick et al. 1981). The degree of mast cell stimulation
(degranulation) and the number of mast cells is highest at sites of
coronary plaque erosion or rupture where the numbers of other
inflammatory cells, macrophages and T lymphocytes, is highest, a
finding supporting the existence of an alternative pathway (Kaartinen et
al. 1994, Kovanen et al. 1995, Kaartinen et al. 1998).
Activated mast cells, co-localized with other inflammatory cells, such as
macrophages and T lymphocytes are found in plaques at all
developmental stages of atherosclerosis and in increasing numbers
with progression of atherosclerotic lesions (Kaartinen et al. 1994,
Kaartinen et al. 1996). Indeed, atherosclerotic lesions obtained from
patients with unstable angina have higher numbers of mast cells
compared to lesions obtained from patients with stable angina
(Kaartinen et al. 1996). In patients with acute myocardial infarction the
local distribution density of mast cells is increased up to 200-fold at the
immediate site of plaque erosion or rupture compared to unaffected
intimal areas (Kovanen et al. 1995).
Tryptase and chymase can activate matrix metalloproteinases,
enzymes produced by macrophages, which are capable of degrading
various components of the extracellular matrix, and so predispose to
the plaque to rupture (Johnson et al. 1998). The presence of pro-
inflammatory cytokines, such as tumor necrosis factor ?, and
interleukin-1, in inflammatory cells and in their surrounding may further
weaken the plaque stability by multiplying inflammatory responses
(Kaartinen et al. 1996).
Clinical data concerning serum concentration of tryptase in patients
with coronary disease is sparse and conflicting. Patients with ST-
segment depression had higher levels of tryptase than patients with
ST-segment elevation (Filipiak et al. 2003). In another study there was
no difference in tryptase levels between patients with myocardial
infarction, unstable angina and controls. (Van Haelst et al. 2001).
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Atherosclerosis and infections
The causative role of infection in the pathogenesis of atherosclerosis
has already been suggested by Sir William Osler, in the early 1900s.
Since then an abundance of experimental and clinical evidence has
accumulated to further support or contradict this hypothesis.
Acute infection increases the concentrations of coagulation proteins
(fibrinogen, F VIII, ? -thromboglobulin, anticardiolipin antibodies) and
decreases the concentration of antithrombin III, causing a
hypercoagulable state (Levi et al. 2003). the prostacycline-
thromboxane ratio moves in the direction of thrombosis and the serum
lipid profile becomes more atherogenic during acute infections. In
patients with severe sepsis and pneumonia, serum total cholesterol,
HDL-cholesterol and LDL-cholesterol decrease (Sammalkorpi 1990).
Enhanced oxidative modification of LDL- cholesterol has been reported
during acute infection (Memon et al. 2000). These aterogenic changes
in lipoproteins are detected in children with acute infection (Liuba et al.
2003). Cytokine synthesis accelerated by acute infections may further
predispose to thromboembolic complications (Levi et al. 2003).
One of the most extensively studied micro-organisms in chronic
infection is Chlamydia pneumoniae (Cpn), an intracellular organism.
Cpn is a common cause of respiratory infections worldwide and
accounts for up to 10 % of all cases of pneumonia (Grayston et al.
1989). The prevalence of antibodies to Cpn in adults is approaching
50% throughout the world, with a 25 % higher prevalence in men than
in women (Grayston et al. 1989). Cpn replicates within the alveolar
cells and uses monocytes and macrophages as vectors when
spreading systemically (Gupta et al. 1997). Cpn has been reported to
replicate in human macrophages, endothelial cells and vascular
smooth muscle cells (Gaydos et al. 1997).
 In a Finnish case-control study patients with acute myocardial
infarction and chronic coronary disease had significantly higher IgG or
IgA antibody titrers against the Cpn antigen compared with those
without symptoms of coronary disease. Moreover, a seroconversion to
the chlamydial lipopolysaccharide (LPS) group antigen was detected in
65 % patients with acute myocardial infarction, but in none of those
with chronic coronary disease and only in one of 41 controls (Saikku et
al. 1988). The Helsinki Hearth Study provided further support for a
causative role of Cpn. In a nested case-control study elevated IgA titres
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against Cpn and the presence of immune-complexes containing Cpn
LPS antigen were associated with increased risk of myocardial
infarction or coronary death, with an odds ratios (OR) of 2.9 (CI 1.5 to
5.4). The serum samples were obtained 3 to 6 months before a cardiac
end point. These results suggest that chronic C. pneumoniae infection
may be a significant risk factor for the progression of CHD (Saikku et
al. 1992). Additionally, the coronary risk associated with increased Cpn
antibody titres was further increased in subjects with ongoing
inflammation, denoted by increased CRP levels (Roivainen et al. 2000).
Recently, two studies including meta-analyses of previous trials have
been published concerning IgA and IgG antibodies to Cpn antigen
(Danesh et al. 2000, Danesh et al. 2002). A combined analysis with
fifteen prospective studies of IgG titres against Cpn and CHD including
3169 cases with non-fatal myocardial infarction or coronary death
yielded an OR of 1.15 (95% CI 0.97-1.36) for CHD. (12) A similar meta-
analysis with ten prospective trials (2283 cases with non-fatal
myocardial infarction or coronary death and 7143 controls) of IgA titres
against Cpn and CHD gave an OR of 1.25 (95% CI 1.03-1.53)(Danesh
et al. 2002).
Cpn-specific structures and antigens have been identified by electron
microscopy and by immunocytochemistry and Cpn nucleotide
sequencies have been identified by the polymerase chain reaction in
carotid and coronary atherosclerotic lesions. Cpn has been found
within early and also in the most advanced atherosclerotic lesions in
carotid and coronary arteries, both from young adults who died in
accidents as well as from patients with symptomatic atherosclerotic
disease (Kuo et al. 1993, Campell et al. 1995). It is noteworthy that Cpn
is rarely identified in normal, nonatherosclerotic vascular specimen
(Kuo et al. 1993, Campell et al. 1995). Moreover, a direct isolation of
Cpn from the atherosclerotic plaque of human coronary artery has
been reported (Ramirez et al. 1996).
Published data supports the associations between chronic, dental
infections and CHD. Men with extended CHD had significantly more
signs of severe dental infection, than men with less extended CHD.
This association remained significant when age, hypertension,
smoking, blood lipids, social class and body mass index were taken
into account (Mattila et al. 1993). In a prospective study with seven
years follow-up, poor dental health significantly predicted a risk of fatal
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and non-fatal coronary events in patients with CHD, even after
adjustment for classic risk factors (Mattila et al. 1995).
Infection may play a part in the development and progression of
primary atherosclerosis over many stages. It may initiate and
perpetuate endothelial damage. Accompanying inflammation activates
the wide response of cytokines, which tend to advance tissue damage.
Markers of chronic persistent infection and inflammation are associated
with an increased risk of cardiovascular events. Infection induces
changes in lipoproteins towards an atherogenic direction and in the
coagulation system towards a thrombogenic direction. Thus, recurrent
or chronic infection may trigger and maintain an inflammatory process
in the vessel wall and exaggerate the progress of atherosclerosis.
However, clinical studies with antibiotic therapies against Cpn have
shown disappointing results in patients with CHD (Andersson et al.
1999, Zahn et al. 2003).
The role of iron
The hypothetical association between iron and atherosclerosis is based
on the concept of the catalytic role of iron in lipid peroxidation. Namely,
transition metals, such as iron, catalyze the Haber-Weiss reaction in
which highly toxic hydroxyl radicals are generated. These hydroxyl
radicals cause oxidative damage by lipid peroxidation (Esterbauer et al.
1992). Oxidatively modified LDL is taken up much more rapidly than
native LDL by specific scavenger receptors on the cell membranes of
monocytes (Esterbauer et al. 1992). Additionally, monocyte-derived
tissue macrophages take up large amounts of oxidatively modified LDL
and turn into foam cells. Endothelial cells, monocytes, macrophages,
lymphocytes and smooth muscle cells are able to induce LDL-oxidation
in vitro, particularly in circumstances, where transition metals such as
iron, is added (Yuan et al. 1998). It has been suggested that the
presence of trace amounts of transition metals, such as iron in culture
medium in vitro is an absolute requirement for cell-mediated oxidation
of LDL (Kritharides et al. 1995). Moreover, pre-treatment with metal
chelators can inhibit LDL-oxidation in macrophages (Lamb et al. 1995).
However, under physiological conditions Fe is tightly bound to carrier
proteins in oxidized, ferric form. Iron must be released from these
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metal-binding proteins and must be converted from the ferric into the
redox-active or ferrous form. In the body iron is bound mostly to
haemoglobin and smaller amounts of it are found in myoglobin, in the
transport protein transferrin and in various enzymes. Iron bound to
ferritin and hemosiderin is stored in the parenchymal cells within the
body.
Existing data suggest that iron, mainly bound in ferritin, occurs within
cytosomal locations, and also in the redox-active form within the acidic
vacuolar apparatus of macrophages. The formation of these radicals in
the phagocytic vesicles is one of the basic defence mechanisms of the
body against invasive organisms.  However, under oxidative stress, the
reaction may lead to lipid peroxidation and accumulation of oxidized,
atherogenic LDL particles, the crucial event in the generation of
atherosclerosis (Lynch et al. 1996). Interestingly, iron loaded
macrophages are found in atherosclerotic lesions, especially in the
shoulder area of atheroma but are not found in normal coronary
arteries obtained from young forensic-autopsy cases (Yuan et al.
1996).
The capacity of macrophages to oxidise LDL is enhanced following
erythrophagocytosis, a process where iron is secreted and
concentration of redox-active metal is thus increased (Yuan et al 1996).
The effect of oxidative stress on iron binding proteins, such as ferritin
and those released from ruptured erythrocytes, have been associated
with a stimulation of LDL-oxidation and up-take by macrophages
(Abdalla et al 1992, Paganga et al 1992).
Within vessel wall macrophages which previously have engulfed iron-
rich structures, such as erythrocytes or aged cells, may release iron
and thus increase concentration of redox-active metals.
Serum ferritin is generally considered to be one of the best
measurements among the biochemical markers of body iron stores.
Serum ferritin is increased in iron load and decreased in iron
deficiency. Ferritin belongs to acute phase proteins and its
concentration is increased by infection and inflammation. Additionally,
malignancies, hepatic and renal diseases may raise ferritin
concentration. Serum iron, transferrin and transferrin saturation are not
as sensitive measurement of iron status as ferritin, nor are these
measurements as easily interpreted.
High serum level of ferritin, which is a marker of body iron stores, has
been reported to be a risk factor for CHD in Finnish men (Salonen et al.
1992). Ferritin, as well as CRP, belongs to acute phase proteins and its
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concentration is increased by inflammation. This association was not
confirmed in two other Scandinavian studies (Magnusson et al. 1994,
Mänttäri et al. 1994) and a Canadian case-control study (Pilote et al.
2000).
Conflicting results have been reported from the epidemiological
association between iron status and CHD, since both high and low
levels of markers related to body iron stores (serum iron, transferrin
saturation and ferritin) have been described to increase the risk of
coronary events (Sullivan 1989, Salonen et al. 1992, Sempos et al.
1994, Reunanen et al. 1995, Mattioli et al. 2002). The latest meta-
analysis of prospective studies found no evidence to support either
strong positive or strong negative association between serum iron and
CHD (Danesh et al. 1999).
In haemochromatosis, absorption of excessive amounts of normal daily
dietary iron results in iron overload. The possibility that
haemochromatosis may be causally associated with the occurrence of
CHD is very interesting. However, no difference in the prevalence of
the haemochromatosis gene mutation (C282Y) has been demonstrated
in patients with CHD or in those with normal coronary arteries (Battiloro
et al. 2000, Bozzini et al. 2002). A registry of nearly 48000 autopsies
performed between 1889 and 1992 reported fewer coronary disease
findings in 41 patients with an iron overload compared to those without
an iron overload (Miller et al. 1994). The results of these controlled
studies do not provide evidence of increased prevalence of CHD in
haemochromatosis or of an increased prevalence of
haemochromatosis in patients with CHD.
Heat shock proteins
Eukaryotic cells defend themselves against extrinsic stress factors,
including heat shock, hypoxia, ischemia, inflammation and exposure to
cytokines and to cellular toxins, such as endotoxins and heavy metals,
by up-regulating the synthesis of a number of proteins in order to
maintain cellular protein homeostasis and to ensure their survival
(Benjamin et al. 1998). For up-regulated heat shock proteins (Hsp), the
primary physiological function is to mediate correct cellular protein
folding, prevent protein aggregation into large damaging complexes, and
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to repair or degrade damaged cellular proteins. By means of this
defense mechanism cells become transiently more tolerant against
extrinsic stress factors. Hsps are either constitutive, (synthesized
constantly) or inducible (normally almost absent under non-stressed
conditions), but synthesized immediately after cell stress (Benjamin et al.
1998). The intracellular locations of Hsp are found mainly in the
cytoplasm, nucleus and/or mitochondria, but under stressed conditions
they are detected on cell surfaces (Benjamin et al. 1998). Various Hsp-
genes have been well conserved throughout evolution. For example, the
identity of nucleotide sequence of the Hsp-70 gene varies from 60-78%
among eukaryotic cells.
The classification of various Hsps is based on their molecular weight and
related function and they are named on the basis of their approximate
molecular weight.  For example, the 60-kilodalton Hsp is Hsp-60. Hsp-
60, Hsp-65 and Hsp-70 are the most extensively studied members of
this family.
Experiments have shown that exposure to oxidized LDL induces Hsp
expression by human endothelial cells (Zhu et al. 1994). Immunization
with Hsp-65 leads to the development of early atherosclerotic lesions in
experimental animals and the lesions are more severe, when the
immunization is combined with high a cholesterol diet (George et al.
1999).
High shear stress was shown to induce Hsp-60 expression in endothelial
cells both in vitro and in vivo, but this phenomenon was not found in
vessel walls exposed to low shear stresses (Hochleitner et al. 2000).
Additionally, high blood pressure leads to up-regulation of Hsp-70 in the
rat aorta (Xu et al. 1995).
Several members of the Hsp family have been detected in the cells of
human atherosclerotic lesions, including macrophages, endothelial and
smooth muscle cells (Kleindienst et al. 1993, Xu et al. 1993).  Elevated
Anti-Hsp-Ab levels have been shown to be associated with human
atherosclerosis. Subjects with carotid atherosclerosis have significantly
higher antibody levels against mycobacterial Hsp-65, a close homologue
of human Hsp-60, than subjects without carotid lesions (Xu et al. 1993).
High levels of Anti-Hsp65-Ab are associated with advanced
atherosclerosis and with the progression of the lesions, and they also
predict mortality in patients with carotid atherosclerosis (Xu et al. 1999).
In recent studies the prevalence of coronary artery disease was shown
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to increase among those subjects who were seropositive for Hsp-60 and
-65 compared with those who are seronegative (Birnie et al. 1998, Zhu
et al. 2001). Furthermore, a strong association between human anti-
Hsp60-Ab level / anti-Hsp65-Ab level and the severity of CHD has been
demonstrated (Birnie et al. 1998, Zhu et al. 2001).
It has been suggested that monoclonal antibodies against Hsp-60
mediate cytotoxity and lysis of those endothelial cells which express
Hsp-60 (Xu et al. 1994). Thus, such antibodies may be harmful and
participate in vascular injury, and importantly, play a role via the
autoimmune mechanism in the pathophysiology of atherosclerosis.
There is a high degree of sequence similarity between bacterial and
human Hsp-60/65.  Indeed, specific antibodies against Hsp-65 obtained
from patients with carotid atherosclerosis have been shown to bind with
high affinity to both mycobacterial Hsp-65 and its human counterpart,
Hsp-60. This high affinity binding causes these cells to lyse in the
presence of complement (complement-mediated cytotoxicity) or
peripheral blood mononuclear cells (antibody-dependent cellular
cytotoxity) (Schett et al. 1995). Additionally, 99% of patient with ACS had
increased antibodies against Cpn-Hsp-60 compared with only 20 % of
stable angina patients and none in control group (Biasucci et al. 2003).
About after one year from an acute event antibodies against Cp-Hsp-60
became weakly positive or negative in the patients. No correlation was
found between antibodies against Cp-Hsp-60 and IgG- antibodies
against Cp. It was suggested that antibodies against Cp-Hsp-60 be
caused by anti-self response related to the high degree of sequence
similarity between human and Cp-Hsp-60, and to be both sensitive and
specific markers of ACS (Biasucci et al. 2003). In nested case-control
study increased IgA antibodies against human Hsp-60 were found to be
a significant risk factor for a coronary event, with an OR 2.0 (95% CI;
1.1-3.6). Moreover, the presence of inflammation, noted as elevated
CRP concentration, increased the risk to 4.6-fold (Huittinen et al. 2002).
Subjects with borderline hypertension had significantly higher Anti-
Hsp65-Ab levels compared with normotensive subjects (Frostegård et al.
1997). Circulating Hsp60 levels were found to be elevated in borderline
hypertension and correlate to arterial intima/media thickness (Pockley et
al. 2000).
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Aims of the study
The studies reported here were designed to investigate the role of some
inflammatory markers in the classification and risk prediction of CHD.
The specific aims were:
1. to study whether markers of activated inflammatory cells can be
used in the diagnostic classification and in the prediction of the
clinical outcome in patients with ACS; the following markers were
studied: monocyte chemoattractant protein-1 (MCP-1) as a
marker of monocytes/macrophages activation, soluble interleukin-
2 receptor (sILr-2) as a marker of T lymphocyte activation and
tryptase as a marker of mast cell activation
2. to study the interaction of CRP with classical risk factors in CHD
risk prediction
3. to study the usefulness of CRP in diagnostic classification and for
the prediction of cardiovascular events in patients with ACS
4. to assess the association of serum iron with the risk of CHD
5. to assess whether Hsps may predict the risk of CHD
Subjects and methods
Helsinki Heart Study population (HHS)
The Helsinki Heart Study was a double-blind, placebo-controlled
primary prevention study performed to test the hypothesis that
increasing HDL-cholesterol and simultaneously decreasing LDL-
cholesterol by the study drug, gemfibrozil, will reduce the
incidence of CHD in dyslipidemic (non-high density lipoprotein
[HDL]-cholesterol > 5.2 mmol/l) men. Study subjects, 40-55 years
of age, were recruited from among 23 531 men, representing 5.6
% of the healthy male population of that age in Finland. These
subjects were employed by two government agencies and five
industrial companies. The selection procedure was carried out
during 1981-1982.  Exclusion criteria were signs or symptoms of
CHD and other physical or mental major illnesses (Mänttäri et al.
1987). After screening, 4081 participants were randomly
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allocated to receive either gemfibrozil 600 mg b.i.d. or a matching
placebo for five years.
After the 5-year study period all participants, including drop-outs,
were informed about their base-line lipid values and gemfibrozil
therapy was offered for a 3.5 year follow-up time.
About two-thirds of the study population (66.3 % of the original
gemfibrozil subjects and 68.5 % of the original placebo subjects)
decided to continue with gemfibrozil therapy.
During the 5-year double blind period the HHS participants
attended follow-up visits every three months. For the additional
3.5-year post-trial follow-up phase the visits were set at 6 month
intervals. A blood sample was taken at every visit.
The study protocol was approved by the Ethics Committee of the
Faculty of Medicine, University of Helsinki, and by the National
Board of Health in Finland.
Acute coronary syndrome patients
The objective for this study was to evaluate, whether inflammatory
markers, such as monocyte chemoattractant protein-1 (MCP-1) as a
marker of monocytes/macrophages activation, soluble interleukin-2
receptor (sILr-2) as a marker of T lymphocyte activation and tryptase
as a marker of mast cell activation, could be used in unselected acutely
hospitalized patients with ischaemic chest pain for classification and
prediction of future coronary events. As established markers of the
inflammatory response, plasma levels of interleukin-6 and C-reactive
protein were also determined. Study patients were recruited from three
emergency hospitals in Helsinki, Finland, including two Helsinki city
hospitals (Malmi and Maria hospitals) and Helsinki University hospital
between July 1998 and April 1999. Both women and men, 40-80 years
of age, with acute ischemic chest pain were included. Exclusion criteria
were recent coronary event (myocardial infarction or revascularisation
within 6 months), acute infection, antimicrobial or corticosteroid
treatment, chronic inflammatory disease and malignancy.
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Diagnostic categories
The patients were grouped into following three categories according to
the clinical course: acute myocardial infarction (AMI), unstable angina
(UA) and acute angina (AP). In fifty-nine patients (44 men, 15 women)
AMI was diagnosed according to the World Health Organization criteria
(Gillum et al. 1984). Thus, at least two of the following criteria were
present: severe ischemic chest pain of > 20 minutes duration, an
increase in cardiac enzymes and diagnostic ECG. Sixty patients (37
men, 23 women) had diagnosis of UA, either Braunwald class IB or
class IIIB (Braunwald 1989). AP was diagnosed in patients with typical,
quickly resolving symptoms, with or without temporary ST-T
depressions and with no elevation of myocyte-specific injury markers.
In this group, there were 64 patients (40 men, 24 women), 11 with
previous exercise ECG-based evidence of myocardial ischemia, and 20
with previous MI or revascularisation procedures, whereas in 33
patients the diagnosis was based on a typical history of effort angina
and on possible ECG changes.
The study protocol was approved by the Ethics Committee of the
Department of Medicine, Helsinki University Central Hospital 1997 and
Ethics Committee of the Department of Medicine, Helsinki City Board of
Health 1998. All the patients gave written informed consent.
Laboratory methods
Helsinki Heart Study population
C-reactive protein (CRP)
Frozen serum samples, drawn at the first visit and at every
screening visit, and stored at -20C, were used for the analyses of
CRP and immunoglobulinA antibodies against human Hsp60
protein. For CRP both base-line and pre-event samples were
used. CRP was analyzed in duplicate using a sandwich enzyme
immunoassay (UC CRP ELISA, Eucardo Laboratory, San Diego,
CA, USA). The limit of detection in this assay was 0.35mg/l,
according to the manufacturer’s data.  The intra-assay and inter-
assay coefficients of variation for a serum with high CRP level
were 3.9% and 8.5%, and for a serum with low CRP level, 9.2%
and 10.8%, respectively. Analyzes were performed at the
National Public Health Institute, Helsinki.
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Heat shock proteins
ImmunoglobulinA antibodies against human Hsp60 protein were
measured in base-line serum samples by an enzyme immunoassay. In
this method microtitre plates were coated with a recombinant human
Hsp60 protein produced in E. coli (Sigma, St. Louis, MO, USA) at a
concentration of 5 µg/mL in phosphate-buffered saline (PBS, pH 7.4) at
+37°C overnight. Serum samples diluted 1 to 50 in PBS containing 10%
fetal bovine serum was added, and the plates incubated at +37°C for 2
hours. The plates were then incubated at +37°C with alkaline
phosphatase-conjugated anti-human IgA for 2 hours. Absorbance was
measured against a blank at 405nm.
Serum iron
Serum iron and iron binding capacity were determined from fresh
samples using routine in-house assays of the laboratory. Ferritin was
measured with a commercial immunoradiometric kit
(Spectria R Ferritin IRMA, Orion Diagnostica, Espoo, Finland).
Acute coronary syndrome patients
Routine blood samples for diagnostic purposes were drawn
immediately upon admission to the hospital. Serum samples for the
measurement of C-reactive protein (CRP) and plasma samples for
measurement of interleukin-6 (IL-6), soluble interleukin-2 receptors
(sIL-2r), monocyte chemoattractant protein-1 (MCP-1) and tryptase
were drawn after hospital admission (on average 7.3 hours after
chest pain started) and 24 hours after the initiation of chest pain.
Samples were stored frozen at -70ºC until thawed and analysed on
a single occasion.
C-reactive protein
The same laboratory method was used for analysis of CRP as
earlier described (page 24) and analyses were performed at the
National Public Health Institute, Helsinki.
40
Monocyte chemoattractant protein-1, soluble interleukine-2
receptors, interleukine-6
A sandwich enzyme immunoassay technique (Quantikine, R&D
Systems) was used for the analyses of the plasma levels of MCP-1,
sIL-2R and IL-6. Analyses were performed at the laboratories of Wihuri
Research Institute and Helsinki University Hospital.
Tryptase
Tryptase was measured by a commercial method, UniCAP-100
Tryptase fluoroenzyme-immunoassay (Pharmacia & Upjohn), at the
Wihuri Research Institute in Helsinki.
The detection limit was 1.0 µg/l. The intra-assay and inter-assay
coefficients of variation for serum with a high tryptase level were 2.2%
and 2.7%, and for serum with a low tryptase level were 3.1% and 3.1%,
respectively.
Statistical methods
Helsinki Heart Study population
The study end-points were non-fatal and fatal myocardial infarction or
cardiac death as defined earlier (Frick et al 1987).
Analysis of variance was used when comparing continuous variables
between cases and controls and for various tertiles, while the chi-
square test was applied to class variables.
The univariate associations between CRP and other risk factors were
studied by comparing mean levels of the other factors in the CRP-
tertiles or by using Pearson’s correlation coefficients. The associations
were first studied in controls only. The results are given with cases and
controls combined, if no substantial differences in the association
patterns were found. Alternatively if there were substantial differences,
the results were presented separately.
A logistic regression analysis (EGRET, Statistics and Epidemiology
Research Corporation, WA, USA) was used to study the association of
defined factors and CHD.
CRP and iron levels were divided into tertiles and the Odds Ratios
(OR) with 95% Confidence Intervals (95% CI) were calculated using
the lowest fractile as the reference (OR=1) for CRP and the middle and
highest fractiles as reference (OR=1) for iron.
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For Anti-Hsp60-Ab, the median was used as a cut-off for high/low,
while for the other risk factors the highest/lowest tertile limit defined the
risk category.
To study joint effects, a new variable was introduced in the models
representing the categories of defined factor (CRP, iron, Anti-Hsp60-
Ab, high/low) and the other risk factor (high/low). This approach is
similar to a stratified analysis, except that all combinations of these two
factors under study are simultaneously present in the calculations. As a
result, the ORs can be compared with each other in all directions. For
example, when subjects with low CRP and low systolic blood pressure
(SBP) are used as a reference (OR=1), one can estimate the relative
importance of high CRP and high SBP as risk factors in this population
by comparing the ORs in high-CRP-low-SBP and low-CRP-high-SBP
categories.
Acute coronary syndrome patients
The study end-points during the follow-up included recurrent unstable
angina, myocardial infarction, coronary revascularisation (percutaneous
coronary intervention, coronary by-pass grafting), and cardiac death.
Analysis of variance was used to compare continuous variables
between patient groups, while the chi-square test was applied to class
variables. Because of the skewed distributions, logarithmic
transformations of the inflammatory plasma marker levels were used in
the calculations. For simplicity the results are given as medians and
ranges or means and standard deviations. Linear regression models
were used to study the associations between the continuous variables.
Logistic regression analyses (EGRET, Statistics and Epidemiology
Research Corporation, WA, USA) were used to study the associations
between the inflammatory markers and the coronary events. The
medians or upper tertile limits were used as cut-off levels for high/low
values. To study joint effects, a new variable was introduced in the
models representing the categories of subjects with high/low levels of
inflammatory markers. Kaplan-Meier life table estimates were used to
determine event-free survival rates in the patient categories.
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Results
Helsinki Heart Study population
Eighty-four of the 2035 subjects on placebo had study end-points (non-
fatal myocardial infarction or cardiac death) whereas 56 end-points
were registered for the 2046 subjects on gemfibrozil therapy, giving a
34 % reduction in CHD risk (p < 0.02) during the 5-year study. During
the post-trial 3.5-year follow-up period, there were 54 and 47 study
end-points in the original gemfibrozil and placebo groups, respectively.
The difference was non significant. Thus, a total of 241 subjects
suffered either myocardial infarction or coronary death over the
combined 8.5-year study and follow-up periods. These subjects were
the cases for the studies I and II. For the study IV sufficient samples of
frozen baseline sera for the analyses were obtained from 215 case-
control pairs.
The controls were subjects who completed the study without coronary
events, matched for drug treatment (gemfibrozil/placebo) and the
recruitment area. The latter was necessary due to the large
geographical variation in CHD rates within the country, since the
participants of the HHS came from the whole country and not just from
the city of Helsinki.
There were no differences in age, smoking habits, blood pressure
(systolic and diastolic blood pressure), body mass, lipid levels or
prevalence of hypertension and diabetes in the treatment groups.
There were differences in the mean levels or proportions of classical
risk factors between the cases and controls, since the study cohort was
matched just for geographical area and experimental drug treatment
(Table 1). Cases were older, and more obese than controls. Fifty-eight
% of the cases were smokers compared to 36% in controls. The cases
had significantly higher systolic and diastolic blood pressure than the
controls. Cholesterol level and total leucocyte counts were significantly
higher and HDL cholesterol level lower in cases compared to control
subjects. Table 2 shows blood levels of the inflammatory markers and
markers related to inflammation in the HHS population.
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Table 1. Baseline characteristics of Helsinki Heart Study population.
Cases (n=241) Controls (n=241)
Mean (SD) Mean (SD) P value
Age, years 48.5 (5) 47.2 (5) < 0.005
Body mass index (kg/m2) 26.9 (3.2) 26.1 (3) < 0.005
Smokers, % 58 36 < 0.01
Systolic RR (mmHg) 148 (16) 141 (16) < 0.001
Diastolic RR (mmHg) 95 (11) 91 (10) < 0.001
Cholesterol (mmol/l) 7.68 (0.9) 7.51 (0.8) < 0.05
HDL cholesterol mmol/l) 1.19 (0.3) 1.30 (0.3) < 0.001
Triglyserides (mmol/l) 2.42 (2.2) 2.0 (1.4) < 0.05
Table 2. Blood levels of inflammatory markers and markers related to
inflammation in Helsinki Heart Study population.
Cases (n=241) Controls (n=241)
Mean (SD) Mean (SD) P value
Baseline CRP (mg/l) 4.48 (5.4) 2.03 (2.3) < 0.001
Pre-event CRP (mg/l) 5.98 (8.3) 3.58 (5.6) < 0.005
Leukocyte count 109/l 6.9 (2.0) 6.1 (1.8) < 0.001
Hsp Ab 12 (6) 12 (7) ns
Cpn Ab 24 (38) 18 (32) ns
Serum iron (µmol/l) 47.2 (4.9) 48.5 (4.6) ns
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C-reactive protein (Study I)
Mean baseline CRP level was significantly higher (p<0.001) in the
cases group than in the control group (Table 2). There was an increase
in mean CRP level in the whole population during the follow-up, but the
mean pre-event CRP was still higher in cases than in controls. The
risks associated with elevated CRP levels either at the baseline or at
the pre-event visits are given in table 1, (Study I).
Gemfibrozil had no effect on CRP levels. Associations of selected
coronary risk factors with CRP at study baseline are shown in table 2,
Study I. Age had no association, whereas subjects with high CRP
concentrations had higher body mass and higher systolic blood
pressure than those with low CRP (table 2, Study I).  There was no
correlation with mean serum total cholesterol level, since all
participants were hypercholesterolemic.  However, a significant inverse
correlation was found between CRP and HDL-cholesterol.
Figure 2 (Study I), presents the associations between CRP, smoking
and physical activity. The mean CRP levels were significantly higher in
smokers compared with both non-smokers and ex-smokers. The
negative correlation between CRP and physical activity as well as
between HDL-cholesterol and CRP as releaved by multiple regression
analyses remained significant among controls.
When baseline CRP level was low, the OR associated with classical
coronary risk factors (HDL-cholesterol, blood pressure, heart rate and
leukocyte count) were of marginal significance only (Table 4, Study I).
The joint effects of high CRP and high levels classical risk factors
studied demonstrated additive increments for CHD risk.
A different pattern was found in the studies on joint effects of CRP and
some newly accepted CHD risk factors or indicators (Table 5, Study I).
High levels of antibodies against oxidized LDL, and antiprothrombin
antibodies as well as high total immunoglobulin G levels were
statistically significant risk indicators irrespective of CRP, but their joint
effects were additive.
Heat shock proteins (Study II)
Although the difference in mean Anti-Hsp60-Ab level between the
cases and control groups was not significant, the coronary risks in the
second and third Anti-Hsp60-Ab tertiles were 1.61 (95% CI 1.01 – 2.59)
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and 1.56 (95% CI 0.99-2.46), respectively, when compared to the
reference tertile. The finding remained significant even after adjustment
for age and smoking. When anti-Hsp60-Ab levels were above the
median value, the coronary risk was significantly increased, even after
adjustment for age and smoking. Further adjustment for CRP level
changed the risk only marginally.
A positive correlation between Anti-Hsp60-Ab level and hypertension
was found in cases. The proportion of subjects with systolic blood
pressure > 150 mmHg (highest tertile of distribution) was 60 % in the
highest Anti-Hsp60-Ab tertile, compared with 42 % in the lowest tertile.
The corresponding proportions of subjects with diastolic BP > 100 mm
Hg (highest tertile of distribution) were 40 % and 36 %, respectively.
An inverse trend (p = 0.07) was observed between Anti-Hsp60-Ab
levels and HDL-cholesterol, with 48 % of the cases in the highest Anti-
Hsp60-Ab tertile having low HDL (<1.1 mmol/l; lowest tertile of
distribution) compared with only 33 % in the lowest Anti-Hsp60-Ab
tertile, respectively. No association was found between cholesterol
level and Anti-Hsp60-Ab level. In the cases, smoking had no influence
on Anti-Hsp60-Ab levels whereas in the controls the proportion of
smokers was 47% in the highest Anti-Hsp60-antibody tertile compared
with 30% in the two lowest tertiles.
The joint effects of Anti-Hsp60-Ab level and the indices of blood
pressure and other classical coronary risk factors are given in Table 1
(Study II). With the exception of high serum triglyceride level the risks
associated with high (low in case of HDL-cholesterol) levels of the
studied  factors were of marginal significance only, when Anti-Hsp60-
Ab level was low. However, the simultaneous occurrence of high levels
of Anti-Hsp60-Ab and other risk factors studied exhibited additive
association.
When either Anti-Hsp60-Ab level or MAP (> 114 mmHg) was high, the
increment in risk, after adjustment with age and smoking, was 1.21
(0.75-2.0) and 1.70 (CI 0.97-2.98), respectively. In simultaneous
occurrence of both factors, the adjusted risk increased significantly.
Serum iron (Study IV)
Serum iron tended to be lower in cases, but the difference did not quite
reach the conventional level of statistical significance (p=0.06). The
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coronary risk of subjects in the lowest iron tertile was 1.4 (95% CI 0.9 -
2.2) and of those in lowest iron quartile 2.1 (95% CI 1.1 – 3.8).
The joint effects of serum iron and two factors reflecting iron status,
iron binding capacity and ferritin, were studied. The highest risk was
associated with the simultaneous occurrence in the lowest tertile of
serum iron and high iron binding capacity, OR 2.2 (CI 1.0 - 4.8), when
compared those with normal serum iron (middle and highest tertile) and
normal or low iron binding capacity. However, no interactions for
coronary risk were found between iron and ferritin levels (Table 1,
Study IV).
The difference in iron levels between smokers and non-smokers was
not significant. In the study of the joint effects, the smokers with low
iron had higher coronary risk, when non-smokers with normal iron level
were the reference group. When CRP was added to the model, the
difference in risk between smokers and non-smokers disappeared.
There was an inverse correlation between iron and CRP as well as
between iron and total leukocyte count. When the markers of
inflammation were normal (CRP, total leukocyte count), the risk
associated with low iron was not significant. However, in the presence
of high CRP level or high total leukocyte count, the OR’s increased
significantly; 3.7 (95% CI 1.9 - 7.3) and 2.5 (95% CI 1.4 - 4.5),
respectively. The subjects with low iron, high CRP and high total
leukocyte count had the greatest incremental increase in coronary risk,
OR 9.8 (95% CI 3.9 - 24.4), (Table 2, Study IV).
In the present study high levels of IgG-class antibodies to Herpes
Simplex Virus Type 1 were used as a marker of infection, as suggested
by the previous observations (Roivainen et al 2000). The joint effects of
low iron, Herpes Simplex Virus infection and CRP are given in Table 3
(Study IV), and the joint effects of low iron, Herpes Simplex Virus
infection and total leukocyte count in Table 4 (Study IV). The
combination of all factors in a single model was not feasible because of
insufficient statistical power due to insufficient numbers of subjects.
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Acute coronary syndrome patients
One hundred and eighty-three patients were studied between
July 1998 and April 1999. There were 121 men and 62 women
whose age range was 40-80 years. Men were older than women
(62+ 9 years and 60 + 10 years, respectively, p=0.026) and 41 %
of men were smokers compared to 34 % of female subjects
(p=ns, Table 1). No significant difference in the prevalence of
CHD or diabetes between men and women was detected. The
use of medication at admission, including ACE inhibitors, b-
blockers, Ca-blockers, diuretics and asperin, was equally
distributed between both sexes (table 3).
Table3.  Baseline characteristics of the acute coronary syndrome patient
population. Mean (SD).
All Men Women p value
Number 183 121 62
Age, years 60 (10) 59 (10) 62 (9) < 0.05
Body mass index (kg/m2) 27 (4) 28 (4) 27 (4) ns
Current smokers, % 38 41 34 ns
History of CHD, % 47 48 45 ns
Diabetes, % 12 12 11 ns
Medication on admission, %
B-blockers 53 53 53 ns
Ca-blockers 21 20 22 ns
ACE-inhibitors 20 20 21 ns
Diuretics 12 10 14 ns
Aspirin 46 46 47 ns
There were no differences in the demographic variables, i.e. age,
sex, and body mass, between the patients with acute myocardial
infarction, unstable angina or acute angina (table 1, Study III).
Patients with AMI had the highest frequency of smoking (51%),
compared with patients with UA (38%) and with AP (29%,
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p<0.05). The patients with AP and UA had higher frequencies of
previous myocardial infarctions and invasive procedures.
Myocardial infarction was the first clinical manifestation of CHD in
41 out of 59 patients with AMI, explaining the lower proportions of
aspirin and beta-blocker users in this group of patients.
CRP and IL-6 (Study III)
The CRP levels did not differ between patient groups (p<0.07). There
was no difference in mean IL-6 levels between patient groups.
Patients using aspirin had significantly lower IL-6 levels 5.13 (+ 5.79)
pg/ml than those without aspirin therapy 9.44 (+10.3) pg/ml, p=0.003.
CRP levels of those on aspirin therapy was 3.53 (+ 4.33) mg/l
compared with those without aspirin 4.22 (+ 8.65) mg/l. The difference
was not significant. There was no correlation between IL-6 and CRP
levels. There was no significant difference in IL-6 and CRP levels
between patients with a study end-point and without a study end-point
(table 4).
Table 4. Blood levels of the inflammatory markers taken at the
hospital admission, categorized by study end-points.
Study end-points*
Fatal Non-fatal No end-points p value
MCP 1 (pg/ml) 354 (220) ** 180 (179) 145 (63) 0.002
sIL-2r (pg/ml) 994 (739) 1034 (760) 807 (656) ns
CRP (mg/l) 6.23 (6.83) 3.99 (8.26) 3.36 (4.17) ns
IL-6 (pg/ml) 11.3 (7.88) 6.90 (9.34) 8.02 (8.14) ns
Tryptase µg/l 9.42 (7.35) 7.25 (5.47) 7.02 (5.59) ns
*Fatal = cardiac deaths, non-fatal = coronary artery by-pass rafting,
percutaneous coronary intervention, acute myocardial infarction and
unstable angina
** Mean (SD)
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MCP-1 (Study III)
There was no statistically significant difference between patient groups
in mean MCP-1 levels.
Patients with high MCP-1 levels (above the median, 144 pg/ml) had a
tendency to increased end-points when compared to patients with low
MCP-1 levels (p = 0.08). Patients who died during the follow-up, had
the highest mean levels of MCP-1 and the differences between patients
with non-fatal end-points (recurrent unstable angina or myocardial
infarction and coronary revascularisation) and patients without end-
points were statistically highly significant. Patients with an early non-
fatal end-point (within 7 days) had significantly higher MCP-1 values
when compared with those with a later (> 7days) non-fatal end-point
(p<0.002). The lowest MCP-1 values were found in patients who
remained event-free during the follow-up period.
Soluble interleukin-2 receptors (Study III)
There was no difference in the level of sIL-2r between patient groups
(table 2). In patients, the risk was higher in those individuals with high
sIL-2r levels (above the median, 720 pg/ml) than in those with low
levels, OR 2.46 (p = 0.017) and adjustment for age and smoking had
no significant effect on the risk. The relative risk in subjects with
simultaneous elevations of MCP-1 and sIL-2r was 2.46 (95% CI 1.06 –
5.74, p = 0.03) as compared to subjects with low levels of both
markers.
Tryptase (Study V)
There were no significant differences in mean tryptase levels between
the patient groups at hospital admission or at 24 hours after the
initiation of chest pain. Moreover, individual serum tryptase levels at the
time of the initial blood sampling and at 24 hours after the onset of
chest pain in the three patient groups did not show any differences.
Serum tryptase levels were positively correlated with age, the levels
increasing by 2.55 µg/L for every 10 years of age (p=0.03).
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Discussion
C-reactive protein (Study I)
C-reactive protein is an acute phase protein and its production is
activated by infection, inflammation and tissue necrosis. During the last
decade it has become evident that a single value of CRP is a predictor
of future cardiovascular events in apparently healthy women (Ridker et
al. 1998, Ridker et al. 2000), men (Kuller et al. 1996, Koenig et al.
1999), and in the elderly population (Tracy et al. 1997). In study I, those
with either increased baseline or pre-event CRP concentrations had a
higher risk of myocardial infarction and cardiac death compared with
those with normal CRP concentrations, a notion in line with previous
data. Additionally it was shown that if both, baseline and pre-event
CRP values were elevated, they represented an even stronger the risk
of myocardial infarction and coronary death compared to the situation
where only one of the two values were elevated. Chronic elevation of
CRP concentration is reported to associate positively with the extent of
atherosclerosis (Heinrich et al. 1995, Tataru et al. 2000). More
importantly, it might be that constantly elevated CRP reflects the more
expanded state of inflammation, instability and vulnaribility of
atherosclerotic plaques and thus increase the risk of vascular events
(Lombardo et al. 2004).
 It is not possible to recommend any CRP concentration levels which
could indicate coronary risk increament for two reasons. First, for CRP
analysis only frozen serum samples, with preservation time of several
years, were used, whereas in clinical practice fresh serum samples are
used. Second, there was a significant difference between baseline and
pre-event CRP levels, both in cases and controls, with a tendency of
increasing CRP levels during the follow-up.
C-reactive protein (Study III)
A trend toward higher values in the C-reactive protein level with
increasing severity of the CHD was observed, both at hospital
admission and at 24 hours after the chest pain started. However, CRP
concentration was not found to associate with the prognosis of CHD.
There are two potential explanations for this finding. First, study
patients with three subtypes of ACS represented patients of everyday
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clinical practice and differed from homogenous study populations of
well-designed prospective studies. The second explanation might be
the use of asperin. Only forty-six percent of the whole study cohort
received aspirin therapy at hospital admission and they had
significantly lower IL-6 concentration compared with those without
aspirin therapy. Similar finding of the effects of asperin on IL-6
concentrations have been reported in patients with stable angina
(Ikonomidis et al. 1999). Furthermore, in those studies where CRP
concentration has been reported to predict cardiovascular events in
unstable angina patients, the majority of the study subjects (83-100%)
had been receiving aspirin therapy (Liuzzo et al. 1994, Morrow et al.
1998).
Heat shock proteins (Study II)
Heat shock proteins (Hsps) are phylogenetically highly conserved
molecules and there is a high degree of sequence similarity between
bacterial and human hsps (Benjamin et al. 1998). Hsps are expressed
constitutively, but the production is markedly elevated by various cellular
injuries. Although Hsps are intracellularly sited, they are  expressed on
the cell surface under stressed conditions, and released into the
circulation (Benjamin et al. 1998). Hsps are found in the circulation of
healthy individuals (Pockley et al. 1999) and in those with cardiovascular
disease (Xu et al. 2000, Pockley et al. 2000).
In the Helsinki Heart Study population, the risk of myocardial infarction or
coronary death, associated with elevated levels of Anti-Hsp60-Ab, was
moderately increased. The risk of coronary events, the ultimate
expression of atherothrombosis, was highest, when both elevated level
of Anti-Hsp60-Ab and high blood pressure were simultaneously present.
This result may be related to the finding that experimentally high shear
stress (Xu et al. 1994) and high blood pressure induces expression of
Hsps (Xu et al. 1995). Additionally, in atherosclerotic lesions, found
located at vascular sites with maximal shear and mechanical stress,
macrophages, endothelial and smooth muscle cells have been shown to
express Hsps (Kleindienst et al. 1993, Xu et al. 1993). Furthermore,
subjects with hypertension have higher levels of circulating Hsp-60
(Pockley et al. 2000) and Anti-Hsp65-Ab (Frostegård et al. 1997) than
subjects with normotension and these concentrations appears to
correlate positively with atherosclerosis (Frostegård et al. 1997, Pockley
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et al. 2000).
Dyslipidemia, simultaneously with elevated levels of Anti-Hsp60-Ab,
significantly increased the risk of coronary events compared to the
situation when neither or only one of these factors was elevated. While
there is no data of the direct association between hypercholesterolemia
and Hsp expression, oxidized  LDL exposure in vitro has been
demonstrated to induce Hsp expression in various cell lines (Zhu et al.
1994). Additionally, immunization with Hsps leads to development of
early atherosclerotic lesions in experimental animals and the lesions
are more severe, when the immunization is combined with
hypercholesterolaemia (George et al. 1999).
The precise significance of Hsps in the pathophysiology of
atherosclerosis is not well-defined, but there are associations between
Hsp immunisation and development of atherosclerosis, shown in
experimental studies (George et al. 1999). Additionally, high levels of
Anti-Hsp-Ab have been reported in patients with atherosclerosis and
these high titres of these are associated with severity the of CHD and
they even predict mortality in patients with carotid atherosclerosis
(Hoppichler et al. 1996, Birnie et al. 1998, Xu et al. 1999, Zhu et al.
2001).
The attachment of Anti-Hsp-Abs to cell surfaces expressing Hsps may
be harmful since these antigen-antibody-complexes may cause
attacked cells to lyse in the presence of complement (complement-
mediated cytotoxicity) or peripheral blood mononuclear cells (antibody-
dependent cellular cytotoxity) (Schett et al. 1995). The high degree of
sequence similarity between bacterial and human Hsp-60/65 might
increase the interaction probability between Hsps and Anti-Hsp-Abs.
Thus, the intensity of reactions against the subject’s own Hsps and the
cross-reactivity with Anti-bacterial Hsp-antibodies are crucial elements
in the involvement of Hsps in atherosclerosis.
Monocyte chemoattractant protein-1 (MCP-1) and soluble
interleukine-2 receptors (sIL-2r) (Study III)
Although there were no differences in the plasma levels of MCP-1 or
sIL-2r between the patient groups, elevated levels (above median) of
MCP-1 and sIL-2r were associated with an increased risk of coronary
events during follow-up in the ACS patients. In subjects who died
during the follow-up, the highest mean levels of MCP-1 were found,
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and the difference between patients with non-fatal end-points and
those without end-points during the follow-up period of 1 year was
statistically highly significant (table 4). Additionally, patients with an
early (within 7 days), non-fatal end-point had significantly higher MCP-1
levels compared to those with a later end-point. In accordance with this
result, increased levels of MCP-1 have been found in patients with
unstable angina and elevated concentration of MCP-1 is associated
with increased risk of myocardial infarction and death (Aukrust et al.
2001, DeLemos et al. 2003).
MCP-1 is the main chemokine, which regulates migration and
infiltration of monocytes-macrophages and T lymphocytes from the
circulation into the arterial wall, a key feature in atherosclerosis (Nelken
et al. 1991).  Interestingly, MCP-1 induces its own production in
monocytes and thus further enhances the focal accumulation of
monocytes (Vestergaard 1997).
In atherosclerotic plaque, MCP-1 expression is related to the amount of
the macrophage infiltration and even to the extent of atherosclerosis.
Accordingly, increased expression of MCP-1 has been found in
macrophage-rich areas of atherosclerotic lesions. In contrast, MCP-1 is
not present in normal artery walls (Nelken et al. 1991, Ylä-Herttuala et
al. 1991). Furthermore, in experimental studies, MCP-1 also induced
pro-inflammatory cytokines (IL-6) in human arterial smooth muscle
cells, matrix metalloproteinases in human fibroblasts, and adhesion
molecules in human monocytes (Terkeltaub et al. 1998). All these
events may be related to the acceleration of atherosclerosis in the
vessel wall.
Serum iron (Study IV)
Iron is an elementary micronutrient which is needed as a component to
form heme and for the electron transfer of metalloenzymes. Most of the
body iron is found in heme compounds, especially hemoglobin and
myoglobin, while trace amounts are incorporated into enzymes.
Nonheme iron is mostly stored as ferritin or hemosiderin in
macrophages and hepatocytes. Only a small fraction, approximately
0.1%, is found in the plasma, bound to the carrier protein, transferrin.
Infection and inflammation are associated with low serum iron levels
despite adequate body iron stores. The precise mechanisms of these
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phenomena are still not fully understood but increased cytokine
production and acute phase reaction are suggested to be involved. In
the HHS population serum iron was correlated inversely with CRP and
leukocyte count. The simultaneous occurrence of low serum iron and
elevated CRP, a marker of inflammation, increased coronary risk
substantially. However, when CRP concentration was high, serum iron
level had no major impact on CHD risk. It should be noted that low
serum iron represents the lower end of iron distribution and is not
indicative to iron deficiency. In the present study, smokers with low iron
levels had higher risk compared to smokers with normal iron levels, but
the difference diminished when adjusted for CRP, further favouring the
idea, that action of low iron might be mediated through factors related
to the inflammatory pathways.
These results are in agreement with the prospective studies
demonstrating an inverse association with iron or transferrin saturation
and CHD (Liao et al. 1994, Magnusson et al. 1994, Sempos et al.
1994, Reunanen et al. 1995). A recent report on a large cohort of
elderly people with a median follow-up time of 4.4 years demonstrated
an increased all-cause mortality of 38% in men and 28% in women with
low serum iron. The risk of coronary death was even higher; 5- fold in
men and 2- fold in women (Corti et al. 1997). However, the opposite
association was found in the Nutrition Canada Survey cohort study
which demonstrated a relationship between high iron and increased
risk of fatal myocardial infarction, but only in the presence of high
cholesterol levels (Morrison et al. 1993).  It should be pointed out that
this result was based on a subgroup analysis with small number of
cases.
The association between iron and CHD has remained controversial.
The results of this study do not support the positive association
between serum iron and atherosclerosis. On the contrary, in this study
there was an inverse trend between low serum iron level and increased
coronary events. However, it has been suggested that the effect of low
serum iron is mediated through factors related to inflammatory
pathways.
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Tryptase (Study V)
Mast cells are found in the normal arterial intima, in fatty streaks and in
increasing numbers in progressively maturing atheromas (Kaartinen et
al. 1994). They particularly accumulate in the shoulder region of
atheromas. Infiltrates of activated mast cells are found at the sites of
coronary plaque erosion or rupture (Kaartinen et al. 1994, Kovanen et
al. 1995). They are co-localized with other inflammatory cells,
macrophages and T lymphocytes (Kaartinen et al. 1994, Kaartinen et
al. 1996). The number of mast cells, like other inflammatory cells,
appears to correlate with the clinical severity of CHD (Kaartinen et al.
1996).
Tryptase is selectively produced by mast cells. As the result of
degranulation of activated mast cells extracellular granules are found in
their vicinity in atheromas (Kovanen et al. 1995). Tryptase may weaken
the fibrous cover of the plaque by activating matrix metalloproteinases,
enzymes capable of degrading various components of the extracellular
matrix (Johnson et al. 1998).
Two types of tryptase are expressed in mast cells, ?- and ?-tryptase.
The ?-type is suggested to be released constitutively from mast cells in
an inactive form and steady basal plasma values are measured in
healthy controls (Kaartinen et al 1994). The ?-type is stored in mast cell
granules and released during degranulation from activated mast cells
(Kovanen et al. 1995).
In the present study the method used to analyze tryptase level, the
UniCAP 100 method, detects both ?- and ?-tryptase. Serum tryptase
levels remained stable in samples taken at admission and 24 hours
after chest pain started, and no differences were detected between the
patient groups. Even in those patients with myocardial infarction whose
samples were collected only 2-5 hours after the onset of chest pain, no
change in serum tryptase levels were detected. There are several
explanations. First, tryptase released from mast cells diffuses into the
circulation and is diluted rapidly and may not reach sufficient
concentration above detection limits in the systemic circulation.
Second, released tryptase quantities may in first place be negligible in
the first place and so remain below detectable concentrations. Third,
since activated mast cells are found at every degree of atherosclerosis,
degranulation and tryptase release may occur chronically, over a long
time period, with no peak release. Stable values do not exclude the
possibility of local activation of coronary mast cells.
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Conclusions
The aim of this study was to examine the role of inflammatory markers
in the classification and risk prediction of CHD. The following results
were obtained from these studies:
1. There were no significant differences in blood concentrations of
MCP-1 as a marker of activated monocytes/macrophages, sILr-2
as a marker of activated T lymphocytes, and tryptase as a marker
of activated mast cells, between patient groups with ACS. Thus,
these markers are not useful in the categorisation of patients with
ACS. However, high concentrations (> median) of MCP-1 and
sILr-2 were associated with an increased risk of coronary events
including cardiac death, recurrent myocardial infarction, unstable
angina, or revascularisation.
2. In otherwise healthy, yet dyslipidemic, middle-aged men, those
with high CRP concentration had a higher risk of myocardial
infarction and coronary death compared to those with normal
CRP concentrations. Moreover, if CRP levels were chronically
incresed, the associated risk was higher compared to the situation
when the baseline or the pre-event value was elevated.
Additionally, the study of joint effects of CRP and classical risk
factors suggested that they were additive for coronary risk.
3. In unselected patient populations representing the everyday
clinical spectrum of ACS, CRP levels at hospital admission was
not useful in the categorisation of patients into subtypes of ACS.
CRP levels were not associated with coronary events during the
follow-up.
4. There was a inverse trend between serum iron level and
increased coronary risk. The effect of low iron on coronary risk is
not independent in the classical sense. Low serum iron is related
to chronic infection and inflammation.
5. There was a positive trend of increased coronary risk with
increasing Anti-Hsp60-Ab levels but the effect was modest
without the simultaneous occurrence of classic risk factors, such
as hypertension and hypercholesterolemia.
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